{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lacerations/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field a64263ad-de5b-4b71-842c-287ff8fe02cd --><h2>Co-amoxiclav </h2><!-- end field a64263ad-de5b-4b71-842c-287ff8fe02cd -->","summary":"","htmlStringContent":"<!-- begin item 2b5bbf9c-8f68-40e7-8611-d2e9ea932347 --><!-- end item 2b5bbf9c-8f68-40e7-8611-d2e9ea932347 -->","topic":{"id":"bc1075da-03fb-510a-aafc-42f8402c77bb","topicId":"c455b3ad-86f5-4c2b-a00d-ceb66ba46f46","topicName":"Lacerations","slug":"lacerations","lastRevised":"Last revised in January 2021","chapters":[{"id":"abcb9c5e-8c70-578e-b2f1-2bfe9e0e6dea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b3295eac-08d7-597e-9bbf-240c812490a5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes"},{"id":"d164a0e0-2763-5ec6-8aaa-1f68fe1d381c","slug":"update","fullItemName":"Update"}]},{"id":"e6d917bb-ce9e-58a6-8b13-cf3e389a6aef","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"83820372-5bd1-5e60-a139-cd76615ac683","slug":"goals","fullItemName":"Goals"},{"id":"15606cb7-089f-5a7d-af3f-d4b9c9b0d2be","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1a9aa28b-0708-5c58-843c-05a09196b471","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"682e483f-7847-5e82-be10-969f896d9533","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0db2153f-bcb4-5382-9178-92d651a01c4e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3929f359-184e-53d4-8aca-a4081b967c1a","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"313e7f7d-a625-5b48-a31d-e5f00ca31462","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0ad26899-0f07-5523-8ea6-17d520df4cc8","slug":"definition","fullItemName":"Definition"},{"id":"e917af1e-ca7f-5ddd-9cb9-1132ce21b4a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe57a056-8e82-56fa-bb79-87f037fb4303","slug":"complications","fullItemName":"Complications"}]},{"id":"e01eac70-aab4-50c3-a90e-7b07194bf1c8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c1be68cd-346e-504f-b22f-e8352fc5c3f6","slug":"assessment","fullItemName":"Assessment"}]},{"id":"35a250d2-9a3b-5287-8afa-d73dfc12c39b","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c6adc10-cc7f-5820-b2da-874e89c9b72b","slug":"laceration-low-infection-risk","fullItemName":"Scenario: Laceration - low infection risk"},{"id":"496fa19f-131c-5dd3-8be3-ae041478b608","slug":"laceration-high-infection-risk","fullItemName":"Scenario: Laceration - high infection risk"},{"id":"9204ec1a-d022-5955-9f74-6b4eb51bf9a9","slug":"laceration-infected","fullItemName":"Scenario: Laceration - infected"}]},{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8f912e41-1ff8-5fce-b9b4-6b3524e8f79b","slug":"tetanus-booster","fullItemName":"Tetanus booster"}]},{"id":"b1fc897d-bfab-5305-bcf1-70e0f4598e5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"18a38028-bff4-54de-948c-9715f3649589","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0132c748-edac-513b-a351-59a838b07e61","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b4b28cd4-4652-528e-aa28-23f341c6a31e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b86d931b-dadb-55a7-92c8-6cdb81ce5d7f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6695afc-2f21-5bf7-907b-68a0fb3a77c4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d4ab79d3-d601-5b9b-b2b5-d3256e138671","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc9ca4ec-c56f-5acc-830c-ccf5c31d5f67","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"36cecbfd-941b-564e-891c-2b018cecfff3","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 039caffd-c8fc-4aa4-9158-a7680164dbbd --><h3>What are the licensed doses?</h3><!-- end field 039caffd-c8fc-4aa4-9158-a7680164dbbd -->","summary":"","htmlStringContent":"<!-- begin item 4dfac21a-0a4c-4eb2-bf30-a7680164d927 --><!-- begin field 34cd025d-3a39-4880-b0ba-a7680164dbbd --><ul><li><strong>Prescribe co-amoxiclav for 5–7 days. The licensed oral doses are:</strong><ul><li><strong>Neonates </strong>— 0.25 mL/kg of 125/31 suspension three times daily.</li><li><strong>Children aged 1 month to 11 months </strong>— 0.25 mL/kg of 125/31 suspension three times daily, dose doubled in severe infection.</li><li><strong>Children aged 1 year to 5 years </strong>— 0.25 mL/kg of 125/31 suspension three times daily <em>or</em> 5 mL of 125/31 suspension three times daily, dose doubled in severe infection.</li><li><strong>Children aged 6 years to 11 years </strong>— 0.15 mL/kg of 250/62 suspension three times daily <em>or</em> 5 mL of 250/62 suspension three times daily, dose doubled in severe infection.</li><li><strong>Adults and children aged 12 years and over </strong>— one 250/125 strength tablet every 8 hours, increased in severe infection to one 500/125 strength tablet every 8 hours.</li></ul></li><li><strong>In renal impairment </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2017a</a>]<strong>:</strong><ul><li>If estimated glomerular filtration rate (eGFR) is 10–30 mL/minute/1.73 m<sup>2</sup>, use the normal dose every 12 hours.</li><li>If eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, use normal dose every 24 hours.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">Cals, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">DynaMed, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF for Children, 2017</a>]</p><!-- end field 34cd025d-3a39-4880-b0ba-a7680164dbbd --><!-- end item 4dfac21a-0a4c-4eb2-bf30-a7680164d927 -->","subChapters":[]},{"id":"0a53ee8b-b501-5a04-9a9c-68b8c2910cdc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0e409734-73df-4afc-b47d-a768016501cd --><h3>What are the contraindications and cautions for co-amoxiclav?</h3><!-- end field 0e409734-73df-4afc-b47d-a768016501cd -->","summary":"","htmlStringContent":"<!-- begin item 8a874a83-4072-4717-9d35-a7680164ff7f --><!-- begin field 1af67267-52bb-4843-a83e-a768016501cd --><ul><li><strong>Do not prescribe </strong><strong>co-amoxiclav</strong> <strong>to people with:</strong><ul><li>A <em>true</em> penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not</em> constitute an allergy to penicillin.</li><li>A history of penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution to</strong> <strong>people with:</strong><ul><li>Hypersensitivity to cephalosporins.</li><li>Hepatic impairment.</li><li>Chronic kidney disease (CKD) — reduce the <a class=\"topic-reference internal-reference\" href=\"/topics/lacerations/prescribing-information/co-amoxiclav/#licensed-doses\">dose</a> if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less. </li><li>Acute or chronic lymphocytic leukaemia (increased risk of erythematous rashes).</li><li>Cytomegalovirus infection (increased risk of erythematous rashes).</li><li>Glandular fever (erythematous rashes common).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>] </p><!-- end field 1af67267-52bb-4843-a83e-a768016501cd --><!-- end item 8a874a83-4072-4717-9d35-a7680164ff7f -->","subChapters":[]},{"id":"9632621c-17cf-5579-bf5d-3839870536b4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 968f45ff-e12e-4774-9098-a76801651e28 --><h3>What adverse effects are associated with co-amoxiclav?</h3><!-- end field 968f45ff-e12e-4774-9098-a76801651e28 -->","summary":"","htmlStringContent":"<!-- begin item 72325bc1-ec2f-4fa1-b9df-a7680165172a --><!-- begin field 613c52b1-b357-4c72-8023-a76801651e28 --><ul><li><strong>The most common adverse effects of co-amoxiclav are</strong> nausea, vomiting, and diarrhoea.<ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Hepatitis and cholestatic jaundice</strong> may occur during or after treatment with co-amoxiclav (frequency unknown).<ul><li>Cholestatic jaundice is more common in people aged over 65 years and in men and has only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment with co-amoxiclav should be appropriate to the indication and should not usually exceed 14 days</li></ul></li><li><strong>Anaphylaxis (delayed or immediate)</strong> is a serious but rare adverse effect of co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Other rare adverse effects include:</strong><ul><li>Skin and subcutaneous tissue disorders, including Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and vasculitis.</li><li>Prolongation of bleeding time and prothrombin time.</li><li>Nervous system disorders, including dizziness, headache, and convulsions (particularly with high doses or in renal impairment).</li><li>Superficial staining of teeth with suspension.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>] </p><!-- end field 613c52b1-b357-4c72-8023-a76801651e28 --><!-- end item 72325bc1-ec2f-4fa1-b9df-a7680165172a -->","subChapters":[]},{"id":"ab679a3d-a3c9-5fd2-a8b1-2d8d26633a48","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0278100f-345f-4731-9d0a-a76801653086 --><h3>What drug interactions are associated with co-amoxiclav?</h3><!-- end field 0278100f-345f-4731-9d0a-a76801653086 -->","summary":"","htmlStringContent":"<!-- begin item 19f72f86-0cc6-4e37-a85e-a76801652ef2 --><!-- begin field 3a284d57-08ae-4aa6-9e3d-a76801653086 --><ul><li><strong>Possible drug interactions with co-amoxiclav include:</strong><ul><li><strong>Allopurinol </strong>— increased risk of rash when co-amoxiclav is given with allopurinol.</li><li><strong>Anticoagulants (for example warfarin) </strong>— prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Consider monitoring the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Methotrexate </strong>— penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of co-amoxiclav.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting and diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions of co-amoxiclav</strong><strong>, </strong>see the <a data-hyperlink-id=\"a0439636-602e-4e32-9a4f-a98f0189989f\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"8133033f-1317-4701-8822-a98f018998c4\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/lacerations/references/\">FSRH, 2017</a>]</p><!-- end field 3a284d57-08ae-4aa6-9e3d-a76801653086 --><!-- end item 19f72f86-0cc6-4e37-a85e-a76801652ef2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}